Base de dados : MEDLINE
Pesquisa : C14.907.940.897.249 [Categoria DeCS]
Referências encontradas : 1182 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 119 ir para página                         

  1 / 1182 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29221579
[Au] Autor:Jog NR; James JA
[Ad] Endereço:Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Okla.
[Ti] Título:Biomarkers in connective tissue diseases.
[So] Source:J Allergy Clin Immunol;140(6):1473-1483, 2017 Dec.
[Is] ISSN:1097-6825
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Autoimmune connective tissue diseases are clinically variable, making biomarkers desirable for assessing future disease risk, supporting early and accurate diagnosis, monitoring disease activity and progression, selecting therapeutics, and assessing treatment response. Because of their correlations with specific clinical characteristics and often with disease progression, autoantibodies and other soluble mediators are considered potential biomarkers. Additional biomarkers might reflect downstream pathologic processes or appear because of ongoing inflammation and damage. Because of overlap between diseases, some biomarkers have limited specificity for a single autoimmune connective tissue disease. This review describes select current biomarkers that aid in the diagnosis and treatment of several major systemic autoimmune connective tissue disorders: systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and anti-neutrophil cytoplasmic antibody-associated vasculitides. Newly proposed biomarkers that target various stages in disease onset or progression are also discussed. Newer approaches to overcome the diversity observed in patients with these diseases and to facilitate personalized disease monitoring and treatment are also addressed.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/diagnóstico
Artrite Reumatoide/diagnóstico
Doenças do Tecido Conjuntivo/diagnóstico
Lúpus Eritematoso Sistêmico/diagnóstico
Escleroderma Sistêmico/diagnóstico
[Mh] Termos MeSH secundário: Animais
Autoanticorpos/metabolismo
Biomarcadores/metabolismo
Seres Humanos
Medicina de Precisão
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Biomarkers)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171210
[St] Status:MEDLINE


  2 / 1182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390440
[Au] Autor:Li XL; Xu PC; Chen T; Yan TK; Jiang JQ; Jia JY; Wei L; Shang WY; Hu SY
[Ad] Endereço:Department of Nephrology.
[Ti] Título:Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis developed from ANCA negative renal limited vasculitis: A case report.
[So] Source:Medicine (Baltimore);96(51):e9128, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: The relationship between antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) and ANCA-negative vasculitis has not been elucidated. PATIENT CONCERNS: A 64-year-old female with edema and proteinuria was admitted. A kidney biopsy indicated focal proliferative nephritis with crescents in 25% of glomeruli. Serum ANCA was negative. Eighteen months later, systemic symptoms emerged and acute kidney injury occurred. Serum ANCA against myeloperoxidase (MPO) turned positive. Repeated kidney biopsy showed more severe lesion than last time. Immunoglobulin (Ig)G was purified from serum obtained before the first kidney biopsy. Weak ANCA which could not be detected in serum was found in IgG. DIAGNOSES: MPO-ANCA-associated AAV developed from ANCA-negative renal-limited AAV. INTERVENTIONS: The patient was treated with glucocorticoid. OUTCOMES: The serum creatinine decreased to 2.17 mg/dL a week later. MPO-ANCA turned negative when re-examined 3 weeks later. No relapse has been observed during follow-up for 6 months. LESSONS: This is the first reported case about the spontaneous transformation from ANCA-negative renal-limited AAV to ANCA-positive systemic vasculitis. There might be a slow process of epitope spreading in the pathogenesis of disease. Physicians should try their best to detect the ANCA in the diagnose and treatment of ANCA-negative AAV.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/diagnóstico
Anticorpos Anticitoplasma de Neutrófilos/sangue
Glomerulonefrite/etiologia
Peroxidase/imunologia
[Mh] Termos MeSH secundário: Lesão Renal Aguda/etiologia
Feminino
Glomerulonefrite/diagnóstico
Seres Humanos
Meia-Idade
Proteinúria/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); EC 1.11.1.7 (Peroxidase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009128


  3 / 1182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29188932
[Au] Autor:Sauranen J; Salmela A; Kahlos K; Antonen J; Ekstrand A; Pettersson T
[Ti] Título:The evolving treatment of ANCA-associated vasculitides.
[So] Source:Duodecim;132(16):1449-55, 2016.
[Is] ISSN:0012-7183
[Cp] País de publicação:Finland
[La] Idioma:eng
[Ab] Resumo:Prevention of organ damage and maintenance of long-term remission are the principal goals for treatment of ANCA-associated vasculitides. This can be accomplished by early diagnosis and swift initiation of remission-inducing agents. Outcome has improved but relapses and glucocorticoid- and cyclophosphamide-related toxicity are still major concerns. For remission induction in generalized disease a combination of glucocorticoids and cyclophosphamide or rituximab is used. Rituximab is suitable especially for younger patients with fertility concerns and when cyclophosphamide avoidance otherwise is desirable. In the treatment of relapses and refractory disease, rituximab has proved effective. As maintenance treatment rituximab prevents relapses more effectively than azathioprine.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/diagnóstico
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/tratamento farmacológico
Ciclofosfamida/uso terapêutico
Glucocorticoides/uso terapêutico
Fatores Imunológicos/uso terapêutico
Imunossupressores/uso terapêutico
Rituximab/uso terapêutico
[Mh] Termos MeSH secundário: Ciclofosfamida/efeitos adversos
Quimioterapia Combinada
Diagnóstico Precoce
Glucocorticoides/efeitos adversos
Seres Humanos
Fatores Imunológicos/efeitos adversos
Imunossupressores/efeitos adversos
Indução de Remissão
Rituximab/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Immunologic Factors); 0 (Immunosuppressive Agents); 4F4X42SYQ6 (Rituximab); 8N3DW7272P (Cyclophosphamide)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  4 / 1182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29213125
[Au] Autor:Nishide M; Kumanogoh A
[Ad] Endereço:Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
[Ti] Título:The role of semaphorins in immune responses and autoimmune rheumatic diseases.
[So] Source:Nat Rev Rheumatol;14(1):19-31, 2018 Jan.
[Is] ISSN:1759-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Semaphorins have a well-characterized role in guiding axon repulsion during development; however, the important contribution of these proteins in immunity is becoming increasingly clear. Immunoregulatory semaphorins, termed 'immune semaphorins', have roles in regulating immune cell activation, differentiation, mobility and migration. These proteins are also intimately associated with the pathogenesis of autoimmune diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This Review discusses the pathogenic functions of immune semaphorins, as well as the potential use of these molecules as diagnostic markers and therapeutic targets for the treatment of autoimmune diseases.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/imunologia
Artrite Reumatoide/imunologia
Doenças Autoimunes/imunologia
Lúpus Eritematoso Sistêmico/imunologia
Doenças Reumáticas/imunologia
Escleroderma Sistêmico/imunologia
Semaforinas/imunologia
[Mh] Termos MeSH secundário: Animais
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/fisiopatologia
Artrite Reumatoide/fisiopatologia
Doenças Autoimunes/fisiopatologia
Doenças Autoimunes/terapia
Biomarcadores/metabolismo
Seres Humanos
Lúpus Eritematoso Sistêmico/fisiopatologia
Camundongos
Polimorfismo de Nucleotídeo Único/genética
Doenças Reumáticas/fisiopatologia
Doenças Reumáticas/terapia
Escleroderma Sistêmico/fisiopatologia
Semaforinas/classificação
Semaforinas/genética
Semaforinas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Semaphorins)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171227
[Lr] Data última revisão:
171227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1038/nrrheum.2017.201


  5 / 1182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27772637
[Au] Autor:Fogo AB; Lusco MA; Najafian B; Alpers CE
[Ad] Endereço:Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN. Electronic address: agnes.fogo@vanderbilt.edu.
[Ti] Título:AJKD Atlas of Renal Pathology: Pauci-immune Necrotizing Crescentic Glomerulonephritis.
[So] Source:Am J Kidney Dis;68(5):e31-e32, 2016 Nov.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/patologia
Glomerulonefrite/patologia
Rim/patologia
[Mh] Termos MeSH secundário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/metabolismo
Membrana Basal Glomerular/metabolismo
Membrana Basal Glomerular/patologia
Membrana Basal Glomerular/ultraestrutura
Glomerulonefrite/metabolismo
Granuloma/patologia
Seres Humanos
Rim/metabolismo
Rim/ultraestrutura
Túbulos Renais/metabolismo
Túbulos Renais/patologia
Túbulos Renais/ultraestrutura
Microscopia
Microscopia Eletrônica
Microscopia de Fluorescência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  6 / 1182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28745689
[Au] Autor:Bulanov NM; Serova AG; Kuznetsova EI; Bulanova ML; Novikov PI; Kozlovskaya LV; Moiseev SV
[Ad] Endereço:I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia.
[Ti] Título:[Kidney injury molecules (KIM-1, MCP-1) and type IV collagen in the assessment of activity of antineutrophil cytoplasmic antibody-associated glomerulonephritis].
[Ti] Título:Molekuly povrezhdeniia pochechnoi tkani (KIM-1, MCP-1) i kollagen IV tipa v otsenke aktivnosti assotsiirovannogo s antineitrofil'nymi tsitoplazmaticheskimi antitelami glomerulonefrita..
[So] Source:Ter Arkh;89(6):48-55, 2017.
[Is] ISSN:0040-3660
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To assess the significance of determining the serum and urinary concentrations of monocyte chemotactic protein-1 (MCP-1), kidney injury molecule-1 (KIM-1), and type IV collagen in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) to estimate the activity of renal involvement in AAV. SUBJECTS AND METHODS: 78 patients (32 men and 46 women) (median age 55 (45; 61) years) with AAV were examined. The patients were divided into 3 groups according to the AAV activity estimated using the Birmingham vasculitis activity Score (BVAS): 1) 25 patients with active ANCA-associated glomerulonephritis (GN); 2) 26 patients with active AAV without renal involvement; 3) 27 patients in sustained AAV remission. The serum and urinary concentrations of the markers were measured by enzyme immunoassay. RESULTS: The urinary concentration of all 3 biomarkers was higher in patients with renal involvement (Group 1); the differences in the levels of MCP-1 and type IV collagen were statistically significant as compared to Groups 2 and 3 (p<0.01), while that in KIM-1 level was only in Group 2. There were statistically significant correlations between the urinary concentration of these biomarkers and the traditional GN activity indices (erythrocyturia, daily proteinuria (DPU), total BVAS scores that reflect renal involvement, as well as serum creatinine levels and estimated glomerular filtration rate (p<0.05). ROC curve analysis showed that the urinary MCP-1 excretion of ≥159 pg/ml had the highest (92%) sensitivity and urinary type IV collagen excretion of ≥3.09 µg/l had the highest (86%) specificity in assessing the activity of ANCA-associated GN. At the same time, their diagnostic value increased in terms of a combination of DPU and ESR (96% sensitivity, 84.9% specificity). CONCLUSION: The urinary excretion of MCP-1, KIM-1, and type IV collagen reflects the severity of local renal inflammation in AAV patients and a study of these indicators is a promising diagnostic tool for assessing the activity of ANCA-associated GN.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos
Anticorpos Anticitoplasma de Neutrófilos/imunologia
Quimiocina CCL2
Colágeno Tipo IV
Glomerulonefrite
Receptor Celular 1 do Vírus da Hepatite A
[Mh] Termos MeSH secundário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/sangue
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/imunologia
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/urina
Biomarcadores/sangue
Biomarcadores/urina
Quimiocina CCL2/sangue
Quimiocina CCL2/imunologia
Quimiocina CCL2/urina
Colágeno Tipo IV/sangue
Colágeno Tipo IV/imunologia
Colágeno Tipo IV/urina
Feminino
Glomerulonefrite/sangue
Glomerulonefrite/imunologia
Glomerulonefrite/urina
Receptor Celular 1 do Vírus da Hepatite A/sangue
Receptor Celular 1 do Vírus da Hepatite A/imunologia
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Biomarkers); 0 (CCL2 protein, human); 0 (Chemokine CCL2); 0 (Collagen Type IV); 0 (HAVCR1 protein, human); 0 (Hepatitis A Virus Cellular Receptor 1)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.17116/terarkh201789648-55


  7 / 1182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29016646
[Au] Autor:Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
[Ad] Endereço:Nephrology Unit, University Hospital of Parma, Italy.
[Ti] Título:Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
[So] Source:PLoS One;12(10):e0185880, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is based on remission-induction and remission-maintenance. Methotrexate is a widely used immunosuppressant but only a few studies explored its role for maintenance in AAV. This trial investigated the efficacy and safety of methotrexate as maintenance therapy for AAV. METHODS: In this single-centre, open-label, randomised trial we compared methotrexate and cyclophosphamide for maintenance in AAV. We enrolled patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), the latter with poor-prognosis factors and/or peripheral neuropathy. Remission was induced with cyclophosphamide. At remission, the patients were randomised to receive methotrexate or to continue with cyclophosphamide for 12 months; after treatment, they were followed for another 12 months. The primary end-point was relapse; secondary end-points included renal outcomes and treatment-related toxicity. RESULTS: Of the 94 enrolled patients, 23 were excluded during remission-induction or did not achieve remission; the remaining 71 were randomised to cyclophosphamide (n = 33) or methotrexate (n = 38). Relapse frequencies at months 12 and 24 after randomisation were not different between the two groups (p = 1.00 and 1.00). Relapse-free survival was also comparable (log-rank test p = 0.99). No differences in relapses were detected between the two treatments when GPA+MPA and EGPA were analysed separately. There were no differences in eGFR at months 12 and 24; proteinuria declined significantly (from diagnosis to month 24) only in the cyclophosphamide group (p = 0.0007). No significant differences in adverse event frequencies were observed. CONCLUSIONS: MTX may be effective and safe for remission-maintenance in AAV. TRIAL REGISTRATION: clinicaltrials.gov NCT00751517.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/tratamento farmacológico
Síndrome de Churg-Strauss/tratamento farmacológico
Ciclofosfamida/uso terapêutico
Granulomatose com Poliangiite/tratamento farmacológico
Imunossupressores/uso terapêutico
Metotrexato/uso terapêutico
Poliangiite Microscópica/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/complicações
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/imunologia
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/mortalidade
Anticorpos Anticitoplasma de Neutrófilos/sangue
Síndrome de Churg-Strauss/complicações
Síndrome de Churg-Strauss/imunologia
Síndrome de Churg-Strauss/mortalidade
Feminino
Granulomatose com Poliangiite/complicações
Granulomatose com Poliangiite/imunologia
Granulomatose com Poliangiite/mortalidade
Seres Humanos
Masculino
Poliangiite Microscópica/complicações
Poliangiite Microscópica/imunologia
Poliangiite Microscópica/mortalidade
Meia-Idade
Segurança do Paciente
Seleção de Pacientes
Doenças do Sistema Nervoso Periférico/complicações
Doenças do Sistema Nervoso Periférico/tratamento farmacológico
Doenças do Sistema Nervoso Periférico/imunologia
Doenças do Sistema Nervoso Periférico/mortalidade
Proteinúria/complicações
Proteinúria/tratamento farmacológico
Proteinúria/imunologia
Proteinúria/mortalidade
Distribuição Aleatória
Recidiva
Indução de Remissão
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Immunosuppressive Agents); 8N3DW7272P (Cyclophosphamide); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171011
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185880


  8 / 1182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28977502
[Au] Autor:de Joode AAE; Sanders JSF; Puéchal X; Guillevin LP; Hiemstra TF; Flossmann O; Rasmussen N; Westman K; Jayne DR; Stegeman CA
[Ad] Endereço:Department of Internal Medicine and Nephrology, University Medical Center Groningen, Groningen, the Netherlands.
[Ti] Título:Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
[So] Source:Rheumatology (Oxford);56(11):1894-1901, 2017 Nov 01.
[Is] ISSN:1462-0332
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objective: We studied whether in ANCA-associated vasculitis patients, duration of AZA maintenance influenced relapse rate during long-term follow-up. Methods: Three hundred and eighty newly diagnosed ANCA-associated vasculitis patients from six European multicentre studies treated with AZA maintenance were included; 58% were male, median age at diagnosis 59.4 years (interquartile range: 48.3-68.2 years); granulomatosis with polyangiitis, n = 236; microscopic polyangiitis, n = 132; or renal limited vasculitis, n = 12. Patients were grouped according to the duration of AZA maintenance after remission induction: ⩽18 months, ⩽24 months, ⩽36 months, ⩽48 months or > 48 months. Primary outcome was relapse-free survival at 60 months. Results: During follow-up, 84 first relapses occurred during AZA-maintenance therapy (1 relapse per 117 patient months) and 71 after withdrawal of AZA (1 relapse/113 months). During the first 12 months after withdrawal, 20 relapses occurred (1 relapse/119 months) and 29 relapses >12 months after withdrawal (1 relapse/186 months). Relapse-free survival at 60 months was 65.3% for patients receiving AZA maintenance >18 months after diagnosis vs 55% for those who discontinued maintenance ⩽18 months (P = 0.11). Relapse-free survival was associated with induction therapy (i.v. vs oral) and ANCA specificity (PR3-ANCA vs MPO-ANCA/negative). Conclusion: Post hoc analysis of combined trial data suggest that stopping AZA maintenance therapy does not lead to a significant increase in relapse rate and AZA maintenance for more than 18 months after diagnosis does not significantly influence relapse-free survival. ANCA specificity has more effect on relapse-free survival than duration of maintenance therapy and should be used to tailor therapy individually.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/tratamento farmacológico
Azatioprina/uso terapêutico
Imunossupressores/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/imunologia
Anticorpos Anticitoplasma de Neutrófilos/imunologia
Intervalo Livre de Doença
Feminino
Seguimentos
Granulomatose com Poliangiite/tratamento farmacológico
Granulomatose com Poliangiite/imunologia
Seres Humanos
Nefropatias/tratamento farmacológico
Nefropatias/imunologia
Quimioterapia de Manutenção
Masculino
Poliangiite Microscópica/tratamento farmacológico
Poliangiite Microscópica/imunologia
Meia-Idade
Mieloblastina/imunologia
Peroxidase/imunologia
Recidiva
Fatores de Tempo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Immunosuppressive Agents); EC 1.11.1.7 (Peroxidase); EC 3.4.21.76 (Myeloblastin); MRK240IY2L (Azathioprine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE
[do] DOI:10.1093/rheumatology/kex281


  9 / 1182 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28968886
[Au] Autor:Pearce FA; Craven A; Merkel PA; Luqmani RA; Watts RA
[Ad] Endereço:Division of Epidemiology and Public Health, University of Nottingham.
[Ti] Título:Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis.
[So] Source:Rheumatology (Oxford);56(11):1962-1969, 2017 Nov 01.
[Is] ISSN:1462-0332
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: There are few data on clinical profiles of ANCA-associated vasculitis (AAV) in different ethnic populations. The aim of this study was to examine the differences in the ANCA type and clinical features of AAV between populations using the Diagnostic and Classification Criteria in Vasculitis Study (DCVAS) dataset. Methods: The DCVAS is an international, multicentre, observational study recruiting in 133 sites. Eight ethnic categories were analysed: Northern European, Caucasian American, Southern European, Middle Eastern/Turkish, Chinese, Japanese, Indian subcontinent and other. ANCA type was categorized as myeloperoxidase (MPO), PR3 and ANCA negative. Organ system involvement was recorded using a standard dataset. Differences were analysed by chi-squared tests using a Bonferroni correction and logistic regression (adjusting for age and sex). Northern European was the reference population. Results: Data from 1217 patients with AAV were available and the 967 (79.5%) patients recruited by rheumatology departments were analysed to reduce confounding by recruitment specialty. There were differences in ANCA type between ethnic categories (P < 0.001): MPO-ANCA was more common than PR3-ANCA in Japanese, Chinese and Southern Europeans; PR3-ANCA was more common in the other groups. Compared with Northern Europeans, Japanese had a nearly 60-fold increased chance of having MPO-ANCA (vs PR3-ANCA) [odds ratio (OR) 59.2 (95% CI 8.0, 440.7), P < 0.001] and Chinese had a nearly 7-times increased chance [OR 6.8 (95% CI 2.6, 17.8), P < 0.001]. Ophthalmologic and otorhinolaryngologic involvement were less common in Japanese and Chinese populations than Northern Europeans; otherwise, there were few differences in organ involvement between ethnic groups. Conclusion: This study confirms the previously observed differential occurrence of MPO-AAV and PR3-AAV between different ethnic groups.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/fisiopatologia
Oftalmopatias/fisiopatologia
Nefropatias/fisiopatologia
Otorrinolaringopatias/fisiopatologia
Dermatopatias/fisiopatologia
[Mh] Termos MeSH secundário: Idoso
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/complicações
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/etnologia
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/imunologia
Anticorpos Anticitoplasma de Neutrófilos/imunologia
Árabes
Grupo com Ancestrais do Continente Asiático
China/epidemiologia
Europa (Continente)/epidemiologia
Grupo com Ancestrais do Continente Europeu
Oftalmopatias/etiologia
Feminino
Doenças Urogenitais Femininas/etiologia
Doenças Urogenitais Femininas/fisiopatologia
Cardiopatias/etiologia
Cardiopatias/fisiopatologia
Seres Humanos
Índia/epidemiologia
Japão/epidemiologia
Nefropatias/etiologia
Masculino
Doenças Urogenitais Masculinas/etiologia
Doenças Urogenitais Masculinas/fisiopatologia
Meia-Idade
Oriente Médio/epidemiologia
Mieloblastina/imunologia
Doenças do Sistema Nervoso/etiologia
Doenças do Sistema Nervoso/fisiopatologia
Razão de Chances
Otorrinolaringopatias/etiologia
Peroxidase/imunologia
Doenças Respiratórias/etiologia
Doenças Respiratórias/fisiopatologia
Dermatopatias/etiologia
Turquia/epidemiologia
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); EC 1.11.1.7 (Peroxidase); EC 3.4.21.76 (Myeloblastin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171003
[St] Status:MEDLINE
[do] DOI:10.1093/rheumatology/kex293


  10 / 1182 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28957561
[Au] Autor:Ungprasert P; Crowson CS; Cartin-Ceba R; Garrity JA; Smith WM; Specks U; Matteson EL; Makol A
[Ad] Endereço:Division of Rheumatology, Department of Internal Medicine.
[Ti] Título:Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study.
[So] Source:Rheumatology (Oxford);56(10):1763-1770, 2017 Oct 01.
[Is] ISSN:1462-0332
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objective: To characterize the clinical correlates and outcome of inflammatory ocular disease (IOD) among patients with ANCA-associated vasculitides (AAV). Methods: Medical records of potential cases of AAV seen at Mayo Clinic from 2003 to 2013, inclusive, were reviewed to identify confirmed cases meeting the diagnosis of AAV using the Chapel Hill Consensus Conference 2012 descriptors. Records of confirmed cases of AAV were then further reviewed for IOD, and clinical characteristics, treatment and outcomes abstracted. Results: A total of 1171 confirmed cases of AAV were identified of which 183 patients (mean age 49.0 years; 51% female; 95% Caucasian) had IOD. The most common manifestation of IOD was injection of the eye (57%) followed by eye pain (46%) and visual acuity loss (18%). Scleritis was the most common type of IOD (22%) followed by episcleritis (21%), orbital inflammation (18%), lacrimal duct stenosis (10%) and uveitis (9%). Oral glucocorticoids were used to treat IOD in the majority of patients (96%). CYC and rituximab were the most frequently used immunosuppressive agents (54 and 36%, respectively). Of those with orbital inflammation, 52% underwent therapeutic surgical intervention. Clinical remission of IOD was achieved in 91% of patients but relapses were seen in 23%. Significant visual acuity loss was observed in only six patients. Conclusion: IOD is a common manifestation of AAV and seen in about 16% of patients with AAV. Scleritis, episcleritis and orbital inflammation are the most common subtypes. Most patients respond well to glucocorticoids and immunosuppression, but relapse of IOD is common.
[Mh] Termos MeSH primário: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/complicações
Oftalmopatias/imunologia
Doenças Orbitárias/imunologia
Esclerite/imunologia
[Mh] Termos MeSH secundário: Adulto
Oftalmopatias/tratamento farmacológico
Oftalmopatias/patologia
Feminino
Glucocorticoides/uso terapêutico
Seres Humanos
Imunossupressores/uso terapêutico
Masculino
Meia-Idade
Doenças Orbitárias/tratamento farmacológico
Doenças Orbitárias/patologia
Recidiva
Estudos Retrospectivos
Esclerite/tratamento farmacológico
Esclerite/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Immunosuppressive Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170929
[St] Status:MEDLINE
[do] DOI:10.1093/rheumatology/kex261



página 1 de 119 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde